 Metastatic estrogen receptor alpha positive ( ERα +) cancers account for most breast cancer mortality. Cancer stem cells ( CSCs) and dense/stiff extracellular matrices are implicated in aggression and therapy resistance. We examined this interplay and<symptom> response<symptom> to mTOR inhibition using ERα + adenocarcinomas from NRL-PRL females in combination with Col1a1